The stock appears overpriced with its high beta causing amplified price movements. Its optimistic future growth seems already factored into the current share price, making it potentially not the best time to buy as it has outpaced its industry peers.
Despite lower forecasted growth, Life Time Group's P/S ratio is on par with industry peers, hinting investor loyalty. However, alignment of P/S ratio with the growth outlook could result in disappointment. Weak revenue outlook puts the share price at risk requiring positive change to justify P/S ratio.
ライフ・タイム・グループ・ホールディングスに関するコメント
コラムToday's Pre-Market Stock Movers: BMY, ADBE, MSTR, AZN and More
Select biotech/pharma names showing strength following ESMO:
$クロビス・オンコロジー(CLVS.US)$ +11.3%, $カーディフ・オンコロジー(CRDF.US)$ +9%, $イマティクス(IMTX.US)$ +8.3%, $IDEAYAバイオサイエンシズ(IDYA.US)$ +8%, $ライラ・セラピューティクス(LYRA.US)$ +5.7%, $POINT Biopharma(PNT.US)$ +5.7%, $エッジワイズ・セラピューティクス(EWTX.US)$ +4.7%, $Concert Pharmaceuticals(CNCE.US)$ +3.6%, $デシフィラ・ファーマシューティカルズ(DCPH.US)$ +3.2%, $ヴェラサイト(VCYT.US)$ +2.6%, $スプリングワークス・セラピューティクス(SWTX.US)$ +2.3%,...
まだコメントはありません